💪 As the expected trading timeline for the TARX IPO has been delayed, UXUY will extend the subscription period for the TARX IPO project to July 15.

🔥 Tarsier Pharma Ltd. is a late clinical-stage ophthalmic biopharmaceutical company focused on innovative therapies for autoimmune and inflammatory eye diseases, aiming to bring new treatment options for sight-threatening ocular conditions.

🔗 Download the UXUY App to unlock more U.S. IPO subscription opportunities:

https://t.co/Nn7SnmA6IQ

#UXUY #TARX #IPO #USStocks